A Prospective Study of False-Positive Diagnosis of Micrometastatic Cells in the Sentinel Lymph Nodes in Colorectal Cancer

2009 ◽  
Vol 16 (8) ◽  
pp. 2166-2169 ◽  
Author(s):  
D. Wiese ◽  
S. Saha ◽  
B. Yestrepsky ◽  
A. Korant ◽  
S. Sirop
2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15141-e15141
Author(s):  
Ronaldo Elkaddoum ◽  
Roland Eid ◽  
Fady Haddad ◽  
Myrna Germanos ◽  
Cybel Mehawej ◽  
...  

e15141 Background: In terms of frequency, colorectal cancer (CRC) is the 3rd cancer in Lebanon with 1093 incidences registered in 2015. To this date not a single screening campaign has been organized in the country. Fecal immunochemical test (FIT) is an advised screening technique. We found it useful to organize a screening campaign using FIT to determine the prevalence of CRC in a population of 3000 healthy Lebanese allowing the extraction of useful data. Methods: 3000 tubes were distributed to Lebanese adults (45-80 years old) at average risk of developing CRC, followed by explanations. FIT analysis was done at the medical genetics unit (UGM) of Saint-Joseph University and patients with positive FIT were asked to undergo further investigations. Results: Out of the 3000 distributed tests, 705 were returned (23.5%) with 459 fully analyzable. The age median was 56 (45-80). Sex ratio F/M 2.3. Out of the 459 patients, 278 (60.5%) showed 0ng/ml, 137 (29.8%) showed 1-79ng/ml, 3 (0.6%) showed 80-99ng/ml (intermediate risk values), 33 (7.1%) showed 100-800ng/ml considered as a positive value and finally 8 (1.7%) showed over range values. Among the 44 positive patients we contacted 41. Out of the 8 (18%) colonoscopies results received: 5 showed hemorrhoids leading to false positive, 1 ulcerative ileitis, 1 tubular adenomas and 1 carcinoma. Conclusions: While it was hard for us to quantify people for whom a free FIT was proposed, the low restitution rate among those who took the test shows the necessity of national screening and sensitization campaigns.


1986 ◽  
Vol 4 (5) ◽  
pp. 730-736 ◽  
Author(s):  
M Granowska ◽  
K E Britton ◽  
J H Shepherd ◽  
C C Nimmon ◽  
S Mather ◽  
...  

Thirty patients presenting with a pelvic mass were entered into a prospective study on the use of radioimmunoscintigraphy with the 123I-labeled monoclonal antibody HMFG2. The imaging data was obtained without knowledge of the clinical data and compared with subsequent surgical findings. A false-positive diagnosis of ovarian cancer was made in five of ten patients subsequently shown not to have ovarian cancer; thus the technique cannot be used as a screening test. A true-positive diagnosis was made in 19 out of 20 patients shown subsequently to have ovarian cancer. In 18 of these patients the distribution of uptake closely fitted the surgical findings. Methods of improving these results are described. In conclusion, radioimmunoscintigraphy is of no use in determining whether a pelvic mass is due to ovarian cancer, but has benefit in the evaluation of chemotherapy and may, in the future, prevent the need for second-look operations in some circumstances.


2018 ◽  
Vol 118 (11) ◽  
pp. 1529-1535 ◽  
Author(s):  
Jenni S. Liikanen ◽  
Marjut H. Leidenius ◽  
Heikki Joensuu ◽  
Jaana H. Vironen ◽  
Tuomo J. Meretoja

Sign in / Sign up

Export Citation Format

Share Document